The U.S. Food and Drug Administration issued a Complete Response Letter to UCB regarding the Belgium-based company’s Biologics License Application for bimekizumab for adults with moderate to severe plaque psoriasis.
Two new companies backed by significant financing that will be used to develop treatments for a wide range of diseases launched: Metagenomi will concentrate on next-generation gene therapies and Kira Pharmaceuticals will tackle complement-mediated diseases.
J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Bristol-Myers Squibb’s experimental drug BMS-986165 helped reduce the severity of the most common form of psoriasis in a mid-stage trial.
Eli Lilly and Company announced today the initiation of the IXORA-R head-to-head clinical trial, designed to evaluate superiority between Taltz (ixekizumab) and Tremfya (guselkumab) in adult patients with moderate-to-severe plaque psoriasis.
Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.